Jia (Jenny) Liu MD PhD· @JiaJennyLiu · X·· 17 小时前评分70
正文 · 原文
Exciting!
Great to have participated in the phase 1 trial G042144 of divarasib led by @RashaCosman from #SVHA and see its phase 3 success at #ESMO26
8 浏览 · 0 赞 · 0 转发 · 0 回复
New standard of care for KRAS G12C mutation positive NSCLC. @FSkoulidis presents Krascendo-1 head to head trial of divarasib vs sotorasib or adagrasib- convincing improving PFS (9.8 m vs 5.7 m, HR 0.58) and OS (17.7m vs 12.0m, HR 0.58)在 X 查看被引用的帖子
来源：Jia (Jenny) Liu MD PhD · x.com